← Back to Calendar
Live Company Data
OQX
Updated
just now
· Data: FMP
Current Price
$48.84
+16.51%
+$6.92 today
Day: $48.70 – $49.13
52-Week Range
Current price is at 54% of 52-week range
⚠️ Financial data is for informational purposes only. Not investment advice. Prices may be delayed.
Indication
ER+/HER2- first-line advanced breast cancer (1L)
Key Notes
persevERA Phase 3 readout expected H1 2026 for giredestrant in first-line ER+/HER2- advanced breast cancer. Roche NDA for giredestrant + everolimus (ESR1-mutated post-CDK4/6 setting) already accepted with PDUFA December 18, 2026. persevERA data will inform whether giredestrant can expand into the frontline setting. Competing directly with camizestrant, imlunestrant, and other oral SERDs. Oral SERD class is the hottest breast cancer space for 2026.
⚠️ Not Investment Advice: This information is provided for educational purposes only.
PDUFA dates are FDA target action dates, not guaranteed approval dates. The FDA may extend the review period,
issue Complete Response Letters, or take unexpected actions. Probability of approval scores are based on
historical base rates and do not account for drug-specific factors. Always consult a financial advisor
before making investment decisions.
Discussion
Share your analysis, research, or questions about this catalyst. No account required.